Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

Part of paid clinical trials in Stanford, California.

Sponsor
Pamela L. Kunz
Study ID
NCT00398320
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Capecitabine — DRUG
    850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
  • Oxaliplatin — DRUG
    130 mg/m2 intravenously on day 1 of a 21 day cycle
  • Bevacizumab — DRUG
    7.5mg/kg Intravenous on day 1 of a 21 day cycle

Study Details

Given the lack of other viable treatment options for metastatic neuroendocrine tumors, contrasted with our positive anecdotal experience, and the relative tolerability of the treatment regimen for colorectal cancer patients, we propose a single-institution phase II trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.

Key Dates

First listed
Nov 10, 2006
Start date
Nov 30, 2006
Status verified
Jan 2017
Primary completion
Oct 31, 2012
Completion
Oct 31, 2012

Study Design

Enrollment
40 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab (Avastin), Oxaliplatin (Eloxatin)

Primary Outcome Measure

12-month Progression Free Survival (PFS) [ Time Frame: PFS assessed every 3 months through 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicineStanfordCalifornia94305-

Find similar trials in Stanford, CA

By condition
Neuroendocrine tumors
By specialty
Oncology
By research site
Stanford University School of Medicine· Stanford, CA

Related Studies